Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo bupropion Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparing Smoking Treatment Programs for Lighter Smokers - 1

NCT00086411
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
nicotine transdermal system, bupropion, Medication Management, Mayo Counseling, placebo patch, placebo bupropion
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Bupropion SR Plus Counseling for Smoking Cessation

NCT01621009
View directory record Official record
Conditions
Tobacco Dependence, Smoking
Interventions
Active bupropion + counseling, Active bupropion, No counseling, Placebo medication + counseling, Placebo medication, No counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

NCT00143364
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
15
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2Phase 3 Interventional

Female Orgasmic Disorder (FOD) and Wellbutrin XL

NCT00248209
View directory record Official record
Conditions
Orgasmic Disorder
Interventions
Wellbutrin XL
Drug
Lead sponsor
Segraves, R., T., M.D., Ph.D.
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

NCT00141206
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Newport Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

NCT00439868
View directory record Official record
Conditions
Depressive Disorder
Interventions
WellbutrinXL, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Effects of Antidepressants on Sexual Functioning

NCT00051259
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Extended-Release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Do Treatments for Smoking Cessation Affect Alcohol Drinking?

NCT00580645
View directory record Official record
Conditions
Alcohol Drinking
Interventions
varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 9, 2026, 10:47 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

NCT00419731
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Bupropion + Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2009 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1

NCT00136747
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Memantine, bupropion, placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 9, 2026, 10:47 PM EDT
Recruiting Phase 3 Interventional

Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)

NCT07766655
View directory record Official record
Conditions
Smoking Cessation
Interventions
AXS-05 (dextromethorphan-bupropion), Bupropion, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Little Rock, Arkansas • Lemon Grove, California • Pomona, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Active, not recruiting Phase 2 Interventional

Combination of Novel Therapies for CKD Comorbid Depression

NCT04422652
View directory record Official record
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

NCT02616315
View directory record Official record
Conditions
Weight Regain Post Bariatric Surgery
Interventions
Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 9, 2026, 10:47 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of Bupropion for Treatment of Adolescent Smoking

NCT00248118
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
13 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 3 Interventional

Prevention of Seasonal Affective Disorder

NCT00046241
View directory record Official record
Conditions
Seasonal Affective Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
43
States / cities
Anchorage, Alaska • Hamden, Connecticut • Boise, Idaho + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 1 Interventional

Seasonal Affective Depression (SAD) Study

NCT00069459
View directory record Official record
Conditions
Depressive Disorder
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 9, 2026, 10:47 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

NCT06098079
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone-Bupropion (NB) Combination, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
140
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Results available

Varenicline and Smoking Cessation in Schizophrenia

NCT01111149
View directory record Official record
Conditions
Schizophrenia, Smoking Cessation
Interventions
Sugar Pill, Varenicline, Bupropion HCl
Other · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 9, 2026, 10:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCT00218231
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder
Interventions
300 mg/day bupropion-sr, 0 mg/day bupropion-sr
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 9, 2026, 10:47 PM EDT